Cytokinetics, Incorporated (NASDAQ: CYTK) today announced that the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-controlled ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE